ESTA's revenue has grown from $41.4M in 2025Q1 to $72.0M in 2026Q3, with year-over-year growth of 33.9% in the latest quarter, and gross margin has held near 69-71%, suggesting sustained international demand and premium pricing.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | -$0.35-36.3% vs -$0.26 | $72M+7.8% vs $67M |
Q3 2026 Aug 6, 2026 | -$0.39-15.8% vs -$0.34 | $68M+2.7% vs $66M |
Q2 2026 May 6, 2026 | -$0.40-12.7% vs -$0.35 | $60M+4.3% vs $57M |
Q1 2026 Feb 24, 2026 | -$0.09+58.1% vs -$0.21 | $65M+1.3% vs $64M |
Establishment Labs (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2026, before the market opens on Thursday, October 29, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results.To participate in the conference call, Dial: (+1) 877-407-8037 (US.
Establishment Labs (NASDAQ: ESTA - Get Free Report) and OraSure Technologies (NASDAQ: OSUR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations. Analyst Recommendations This is a summary of
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States. The approval adds 28 new sizes to the Motiva U.S. portfolio, including implants as sm.
Benchmark ESTA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Establishment Labs Holdings Inc. (ESTA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $67.02 | $1.97B | -53.03 | 27.14% | -14.56% | -203.65% | — | |
| $166.00 | $11.89B | 23.97 | 0.9% | 11.83% | 11.76% | — | |
| $13.33 | $766.22M | 10.21 | -6.16% | 20.69% | 11.8% | — | |
| $12.37 | $154.54M | -52.77 | 14.52% | -7.12% | -74.71% | — | |
| $7.44 | $1.14B | -13.48 | 24.95% | -10.35% | -547.17% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — |
Establishment Labs Holdings Inc. (ESTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Establishment Labs Holdings Inc. (ESTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 15, 2026·SEC
Aug 6, 2026·SEC
Get notified when ESTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Establishment Labs Holdings Inc. (ESTA) stock FAQ — growth, dividends, profitability & financials explained
Establishment Labs Holdings Inc. (ESTA) reported $264.0M in revenue over the trailing twelve months. Revenue was $211.1M in fiscal year 2025. That is 966% more than the $19.8M of fiscal year 2016.
Establishment Labs Holdings Inc. (ESTA) grew revenue by 38.3% over the trailing twelve months, compared with the twelve months before.
No. Establishment Labs Holdings Inc. (ESTA) reported a net loss of $38.5M over the trailing twelve months.
Establishment Labs Holdings Inc. (ESTA) had a return on equity (ROE) of -203.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Establishment Labs Holdings Inc. (ESTA) had negative free cash flow of $22.0M over the trailing twelve months.
